Peptide Antibiotics Market (By Product Type; By Disease; By Route Of Administration: Oral, Injectable, Topical; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Peptide Antibiotics Market 

5.1. COVID-19 Landscape: Peptide Antibiotics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Peptide Antibiotics Market, By Product Type

8.1. Peptide Antibiotics Market, by Product Type, 2022-2030

8.1.1. Ribosomal Synthesized Peptide Antibiotics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Non-Ribosomal Synthesized Peptide Antibiotics

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Peptide Antibiotics Market, By Disease

9.1. Peptide Antibiotics Market, by Disease e, 2022-2030

9.1.1. Skin Infection

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. HABP/VABP

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Blood Stream Infection

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Peptide Antibiotics Market, By Route of Administration 

10.1. Peptide Antibiotics Market, by Route of Administration, 2022-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Injectable

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Topical

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Peptide Antibiotics Market, By Distribution Channel 

11.1. Peptide Antibiotics Market, by Distribution Channel, 2022-2030

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Peptide Antibiotics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Disease (2017-2030)

12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Disease (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Disease (2017-2030)

12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Disease (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Disease (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Disease (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Disease (2017-2030)

12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Disease (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Disease (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Disease (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Disease (2017-2030)

12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Disease (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Disease (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Disease (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Disease (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Disease (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Merck & Co., Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. AbbVie Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. GSK Group of Companies

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Sandoz International GmbH

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Xellia Pharmaceuticals

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. AuroMedics Pharma LLC

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Theravance Biopharma

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms